Publications

Find at Harvard

14 Jul 2009
First Look

First Look: July 14

Course MaterialsThe DiagnoFirst Opportunity Harvard Business School Case 309-112 John Mason, a principle at Oldwell Partners, was facing a decision of whether or not to invest in DiagnoFirst, a molecular diagnostics firm. DiagnoFirst's key product was a View Details

Keywords: Martha Lagace

03 Mar 2015
First Look

First Look: March 3

a lower price but charge more for the cartridges necessary to run a sample and earn its primary revenue from these cartridges. The third model would see GenapSys sell its device at or around cost, but use the data customers generated to create a proprietary database of... View Details

Keywords: Sean Silverthorne

02 Jul 2001
Research & Ideas

Ray A. Goldberg

issues," he beams, "from land reform in Mexico to the development of the genetically modified tomato." "The genetic research revolution is changing our global economy and society more... View Details

Keywords: by Staff; Agriculture & Agribusiness

October 2001 (Revised March 2008)
Case

Anagene, Inc.

By: Robert S. Kaplan and Christina L. Darwall

An entrepreneurial, publicly traded biotech company has begun production and sales of its core product--cartridges that permit DNA samples to be analyzed on a microchip. In the early quarters, sales are difficult to forecast and the company has experienced fluctuating... View Details

Keywords: Cost Accounting; Financial Reporting; Production; Performance Capacity; Risk and Uncertainty; Genetics; Governing and Advisory Boards; Biotechnology Industry; California

June 1997 (Revised September 1997)
Case

Genset Initial Public Offering (B)

By: Paul A. Gompers and Jeffrey M. Anapolsky

Supplements the (A) case. View Details

Keywords: Business Model; Initial Public Offering; Genetics; Going Public; Management Teams; Biotechnology Industry; France; United States

June 1997 (Revised March 2001)
Case

Genset Initial Public Offering (A)

By: Paul A. Gompers and Jeffrey M. Anapolsky

Pascal Brandys, founder and CEO of Genset, must decide whether to take this young biotechnology company public. If so, should he do a dual offering in both France and the U.S.? The case also explores the business models in genomics research. View Details

Keywords: Business Model; Initial Public Offering; Genetics; Going Public; Management Teams; Biotechnology Industry; France; United States

October 2010 (Revised November 2010)
Background Note

Plavix: Drugs in the Age of Personalized Medicine

By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon

PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even... View Details

Keywords: Health Care and Treatment; Product Positioning; Business and Government Relations; Genetics; Competitive Strategy; Pharmaceutical Industry

August 2007
Teaching Note

Teva Pharmaceutical Industries, Ltd (TN)

By: Tarun Khanna and Krishna G. Palepu

Teaching note to 707441. View Details

Keywords: Growth and Development Strategy; Cost; Competitive Strategy; Adoption; Emerging Markets; Change; Multinational Firms and Management; Genetics; Pharmaceutical Industry; India

07 Apr 2003
Research & Ideas

Three Steps for Crisis Prevention

genetically modified foods in Europe. Betting the company on a "life sciences" vision, Shapiro had sold or spun off Monsanto's traditional chemical businesses and moved aggressively to acquire seed companies. Dazzled by the... View Details

Keywords: by Michael D. Watkins & Max H. Bazerman

24 Sep 2012
Research & Ideas

Why Do We Tax?

age, gender, height, and race. The most provocative, however, is for genetics. Once we know and understand genetic information better, we could, in principle, do a very good job of inferring individuals' innate abilities from the View Details

Keywords: by Martha Lagace; Legal Services

January 2009 (Revised July 2010)
Case

iZumi

By: Robert F. Higgins, Jacob Ian Broder-Fingert, Eliot Sherman and Sidhartha Palani

Presents the issues faced while building an innovative company in an emerging space with new intellectual property from the perspective of a venture capitalist. Beth Seidenberg, a partner at the venture capital firm Kleiner Perkins Caufield & Byers (KPCB), had helped... View Details

Keywords: Entrepreneurship; Venture Capital; Globalized Markets and Industries; Innovation and Management; Intellectual Property; Rights; Genetics; Financial Services Industry; Health Industry

12 Nov 2015
Research & Ideas

Can Consumers be Trusted with Their Own Health Care?

reveals a person’s genetically based health risk across dozens of disease categories. 23andMe test results showed one patient at higher risk of liver and bowel cancer—and that made sense, given family history. The patient discussed the... View Details

Keywords: by Dina Gerdeman; Health

05 Dec 2013
Op-Ed

Encourage Breakthrough Health Care by Competing on Products Rather Than Patents

Like many people interested in the tangled connections between health care progress and intellectual property rights, I avidly followed the Myriad Genetics case, decided by the Supreme Court this June 13. In sum, molecular diagnostics... View Details

Keywords: by Richard G. Hamermesh; Biotechnology; Health

20 Dec 2004
Research & Ideas

How an Order Views Your Company

about customers and products or services. But, because of increasingly intense competition, one now had to look at individual orders. My research assistant (at the time) and I wrote a case with such detail that it proved to be very popular and useful. It is like having... View Details

Keywords: by Sarah Jane Johnston

November 2006 (Revised March 2008)
Case

The Harvard Stem Cell Institute

By: William A. Sahlman

Describes a set of issues confronting the leaders of the Harvard Stem Cell Institute, an innovative cross-university effort to accelerate scientific discovery and translation in the domain of stem cells. Covers a wide range of topics, including understanding how... View Details

Keywords: Talent and Talent Management; Higher Education; Entrepreneurship; Collaborative Innovation and Invention; Intellectual Property; Research and Development; Genetics; Biotechnology Industry; Health Industry; Massachusetts